Crossmark

A randomised, active- and placebo-controlled, three-period crossover trial to investigate short-term effects of the dipeptidyl peptidase-4 inhibitor linagliptin on macro- and microvascular endothelial function in type 2 diabetes

Crossref DOI link: https://doi.org/10.1186/s12933-016-0493-3

Published Online: 2017-01-21

Published Print: 2017-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Jax, Thomas

Stirban, Alin

Terjung, Arne

Esmaeili, Habib

Berk, Andreas

Thiemann, Sandra

Chilton, Robert

von Eynatten, Maximilian

Marx, Nikolaus
Clinical Trials ^BETA

Clinical trials referenced in this document:

nct01703286 at ClinicalTrials.gov

Documents that mention this clinical trial

A randomised, active- and placebo-controlled, three-period crossover trial to investigate short-term effects of the dipeptidyl peptidase-4 inhibitor linagliptin on macro- and microvascular endothelial function in type 2 diabetes
https://doi.org/10.1186/s12933-016-0493-3
Funding

Funding for this research was provided by:

Boehringer Ingelheim
License Information

Text and Data Mining valid from 2017-01-21

Version of Record valid from 2017-01-21
More Information

Article History

Received: 22 July 2016

Accepted: 28 December 2016

First Online: 21 January 2017

Document is current

Any future updates will be listed below